Article
A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.
Cell reports. Medicine - 21 Nov 2023
Long Jun, Chen Xinjie, Shen Yan, Lei Yichen, Mu Lili, Wang Zhen, Xiang Rufang, Gao Wenhui, Wang Lining, Wang Ling, Jiang Jieling, Zhang Wenjun, Lu Huina, Dong Yan, Ding Yi, Zhu Honghu, Hong Dengli, Sun Yi Eve, Hu Jiong, Liang Aibin
Abstract excerpt
Internal tandem duplication mutations of the FMS-like tyrosine kinase-3 (FLT3-ITDs) occur in 25%-30% of patients with acute myeloid leukemia (AML) and are associated with dismal prognosis. Although FLT3 inhibitors have demonstrated initial clinical efficacy, the overall outcome of patients with F...
Topics
- Animals
- Mice
- Humans
- Tumor Suppressor Protein p53
- Leukemia, Myeloid, Acute
- Mutation
- Prognosis
- Treatment Outcome
- Protein Kinase Inhibitors
- fms-Like Tyrosine Kinase 3